Please try another search
Bio-Techne Corporation reported earnings results for the first quarter ended September 30, 2024. For the first quarter, the company reported sales was USD 289.46 million compared to USD 276.94 million a year ago. Net income was USD 33.6 million compared to USD 50.99 million a year ago. Basic earnings per share from continuing operations was USD 0.21 compared to USD 0.32 a year ago. Diluted earnings per share from continuing operations was USD 0.21 compared to USD 0.31 a year ago.
Period Ending: | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 |
---|---|---|---|---|
Total Revenue | 289.46 | 306.1 | 303.43 | 272.6 |
Gross Profit | 188.1 | 201.71 | 205.43 | 177.94 |
Operating Income | 52.52 | 68.7 | 72.02 | 50.14 |
Net Income | 33.6 | 40.59 | 49.06 | 27.46 |
Period Ending: | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 |
---|---|---|---|---|
Total Assets | 2736.02 | 2703.87 | 2721.17 | 2730.75 |
Total Liabilities | 597.37 | 635.02 | 706.8 | 767.19 |
Total Equity | 2138.65 | 2068.85 | 2014.38 | 1963.56 |
Period Ending: | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 |
---|---|---|---|---|
Period Length: | 0 Months | 0 Months | 0 Months | 0 Months |
Cash From Operating Activities | 63.89 | 75.5 | 80.99 | 83.12 |
Cash From Investing Activities | -21.68 | -8.81 | -16.44 | -23.67 |
Cash From Financing Activities | -11.57 | -60.1 | -52.42 | -81.4 |
Net Change in Cash | 35.75 | 11.88 | 9.78 | -18.53 |
Unlock access to over 1000 metrics with InvestingPro
View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review